News | December 24, 2021
Indian Pharmaceutical Market grew at 6.6 pc in November
Flattish volume growth and subdued new launches were key factors for last month
Flattish volume growth and subdued new launches were key factors for last month
The revolutionary new nano coating is easy to apply and rejects liquid-based contagions like COVID-19/SARS-CoV-2 and variants, influenzas, and rhinoviruses and is available via ready-to-use sprays or pre-treated air filters
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The approval is for Cytomegalovirus, a type of Herpes virus
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
